Home>Topics>Companies>Ranbaxy Laboratories

Ranbaxy Laboratories

  1. All
  2. Commentary
  3. Headlines
  1. UPDATE 1-India's Sun Pharma open to large acquisitions post Ranbaxy deal

    Headlines

    Wed, 25 Mar 2015

    * To boost annual R&D spending to about $300 mln (Adds managing director comments)

  2. India's Sun Pharma open to large acquisitions post Ranbaxy deal

    Headlines

    Wed, 25 Mar 2015

    MUMBAI, March 25 (Reuters) - Sun Pharmaceutical Industries Ltd, India's largest drugmaker by sales, said on Wednesday its $3.2 billion acquisition of smaller rival Ranbaxy Laboratories Ltd will not restrict it from making further large acquisitions.

  3. U.S. judge denies Ranbaxy bid to reinstate approvals for Valcyte, Nexium copies

    Headlines

    Sat, 28 Feb 2015

    MUMBAI, Feb 28 (Reuters) - A U.S. federal judge has denied Indian generic drugmaker Ranbaxy Laboratories Ltd 's bid to reinstate approvals granted to it to launch the first copies of the heartburn...

  4. Sun Appears Cheap Even After Receiving Nod from Competition Commission of India for Ranbaxy Merger

    Commentary

    Thu, 11 Dec 2014

    Sun Pharmaceuticals Industries and Ranbaxy , came through earlier this week ..... positive on the merger, as we believe Ranbaxy 's OTC and specialty drugs portfolio ..... are also present in the acquired Ranbaxy business. We believe the stock is

  5. Sun's Gross Profit Expands Driven by U.S. Subsidiary Price Increases; Shares Fairly Priced

    Commentary

    Sun, 16 Nov 2014

    Quarterly revenue for the yet-to-merge Ranbaxy business was up 16% and profit turned ..... prior period and accounted for 44% of Ranbaxy 's quarterly sales). We believe ..... further enhanced with the addition of Ranbaxy to its portfolio.

  6. Upgrading Sun's Fair Value as we Include Ranbaxy in our Forecast; Narrow Moat Remains Intact

    Commentary

    Sun, 9 Nov 2014

    largely the result of incorporating Ranbaxy financials into our forecast starting 1 April 2014. We believe the Ranbaxy acquisition will strengthen Sun ..... to expand the operating margins of Ranbaxy post-merger. These include manufacturing

  7. Sun Strengthens Its Complex Drug Capabilities as First-quarter Results Remain on Track

    Commentary

    Thu, 14 Aug 2014

    fair value estimate for Sun Pharmaceuticals as we update our model for recent performance and integrate the acquisition of Ranbaxy into our forecast. We also are maintaining our narrow moat rating for the company. Sun continues to post strong growth

  8. ‘Trying to Recapture the Magic’: The Strategy Behind the Pharma M&A Rush

    Headlines

    Fri, 30 May 2014

    April bought Ranbaxy Laboratories for $4 billion from Japan’s Daiichi Sankyo . And French pharmaceutical ..... purchase of Ranbaxy Laboratories , the latter ..... Japan’s Daiichi Sankyo in 2008 bought a 64% stake in Ranbaxy for $4.2

  9. Sun's Unsustainably High Margins Ahead of Our Expectations

    Commentary

    Fri, 30 May 2014

    but we remain concerned about possible margin pressure from internal regulatory issues and the upcoming integration of Ranbaxy . Sun's U.S. business continued to lead the charge with 43% growth, as currency benefits and pricing power in many

  10. Sun Acquires Struggling Ranbaxy at Half the Price Daichii Paid for a Controlling Stake in 2008

    Commentary

    Mon, 7 Apr 2014

    acquire the ailing Indian pharmaceutical company Ranbaxy in an all-equity transaction. Each Ranbaxy shareholder will receive 0.8 shares of Sun ..... quality control and regulatory problems plaguing Ranbaxy 's recent performance. Assuming Sun can successfully

« Prev123Next »
Content Partners